This trial is testing a new cancer drug, Zotatifin, to see if it is safe and effective. Treatment and evaluations will be done every 21 days.
20 Primary · 11 Secondary · Reporting Duration: From start of study therapy to the first documentation of disease progression or death from any cause, which ever came first, assessed up to 100 months
228 Total Participants · 12 Treatment Groups
Primary Treatment: eFT226 · No Placebo Group · Phase 1 & 2
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: